FDA’s Postmarketing Powers Force Shionogi To Withdraw Rybix ODT
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency says Shionogi’s orally disintegrating tramadol is misbranded because the firm did not submit a post-marketing trial protocol in time, but the company states the trial is not worth the expense and will withdraw the product.